Background
On August 14, 2000, the Food and Drug Administration
released a document entitled “Enforcement
Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals” to provide guidance to
third-party and hospitals reprocessors about their responsibilities as manufacturers engaged in
reprocessing devices labeled for single use under the Federal Food, Drug, and Cosmetic Act (the Act),
as amended by the Safe Medical Devices Act of 1990, the Medical Device Amendments of 1992, and
the Food and Drug Modernization Act of 1997. Third-party and hospital reprocessors of single-use
devices (SUDs) are subject to all the regulatory requirements currently applicable to original equipment
manufacturers, including premarket submission requirements (Section 513 and 515 of the Act; 21 Code
of Federal Regulations
Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals” to provide guidance to
third-party and hospitals reprocessors about their responsibilities as manufacturers engaged in
reprocessing devices labeled for single use under the Federal Food, Drug, and Cosmetic Act (the Act),
as amended by the Safe Medical Devices Act of 1990, the Medical Device Amendments of 1992, and
the Food and Drug Modernization Act of 1997. Third-party and hospital reprocessors of single-use
devices (SUDs) are subject to all the regulatory requirements currently applicable to original equipment
manufacturers, including premarket submission requirements (Section 513 and 515 of the Act; 21 Code
of Federal Regulations
Parts 807 and 814).
Since its release on August 14, 2000, the agency has
received numerous questions about the
enforcement
priorities guidance. The following
questions and answers are meant as clarification of the original document. This guidance will be updated as the need
arises.
The
Least Burdensome Approach
We believe FDA should consider the least burdensome
approach in all areas of medical device
regulation. This
guidance reflects our careful review of the relevant scientific and legal
requirements and what we believe is the least burdensome way
for you to comply with those requirements.
However, if you believe that an alternative approach
would be less burdensome, please contact us so we can
consider your point of view. You may send your written comments to the contact person listed in the preface to this guidance or to the CDRH Ombudsman. Comprehensive information on CDRH's
Ombudsman, including ways to contact him, can be found on the Internet at
consider your point of view. You may send your written comments to the contact person listed in the preface to this guidance or to the CDRH Ombudsman. Comprehensive information on CDRH's
Ombudsman, including ways to contact him, can be found on the Internet at
Question related to
SELECTION OF A
THIRD-PARTY REPROCESSOR
Question. How can I obtain information about third-party reprocessors of
single-use devices (SUDs)?
Answer. At this time, FDA cannot provide a list of
reprocessors because our registration and listing database was not designed to identify third-party
reprocessors. We plan to create a
specific code that will identify reprocessors.
To
help you select a third-party reprocessor, we suggest you talk with other
hospitals to determine their experiences with
third-party reprocessors and arrange to visit the reprocessors’
facilities. In addition, you may
consider asking a potential reprocessor the following questions:
·When did FDA last inspect your facility?What were the results of that inspection?
·Do you have documentation that demonstrates
that your company has been cleared/approved by FDA to reprocess SUDs?
·How do you monitor the manufacturing
processes and what records do you maintain in order to comply with FDA's Quality System regulation?
·What aspects of your overall process have
been validated, for example, cleaning, packaging, sterilization?
·Has your company set limits on the number of
times a SUDcan be reprocessed?If yes, how did you determine the number of times a
SUD can be reprocessed?What procedures
do you have in
place to ensure that a
SUD is not reprocessed beyond the set number of times?
To obtain the 483
inspection report from a reprocessor’s most recent FDA inspection, contact
FDA's
Freedom of Information Staff by fax at 301-443-1719 or 301-443-1726. You also can obtain
information about a reprocessor’s inspection history at http://www.fda.gov/cdrh/foicdrh.html.
Freedom of Information Staff by fax at 301-443-1719 or 301-443-1726. You also can obtain
information about a reprocessor’s inspection history at http://www.fda.gov/cdrh/foicdrh.html.
Question related to
MEDICAL DEVICE REPORTING
Question. What
are FDA's requirements for reporting an adverse event with a SUD reprocessed by
the hospital?
Answer. If a hospital reprocesses a device that was
previously marketed as a single-use device, FDA
considers the hospital to be the manufacturer of that device and subject to the same adverse event
reporting requirements (Medical Device Reporting or "MDR") as original equipment manufacturers or
commercial reprocessors. A manufacturer is defined in Title 21 of the Code of Federal Regulations
(CFR) at 803.3(o) as "any person who manufactures, prepares, propa-gates, compounds, assembles,
or processes a device by chemical, physical, biological, or other procedure." The manufacturer MDR
considers the hospital to be the manufacturer of that device and subject to the same adverse event
reporting requirements (Medical Device Reporting or "MDR") as original equipment manufacturers or
commercial reprocessors. A manufacturer is defined in Title 21 of the Code of Federal Regulations
(CFR) at 803.3(o) as "any person who manufactures, prepares, propa-gates, compounds, assembles,
or processes a device by chemical, physical, biological, or other procedure." The manufacturer MDR
requirements are in
addition to the hospital's current user facility adverse event reporting
requirements.
Information on MDR requirements is available on the Internet at http://www.fda.gov/cdrh/mdr.html and
http://www.fda.gov/cdrh/osb/guidance/1334.pdf.
Information on MDR requirements is available on the Internet at http://www.fda.gov/cdrh/mdr.html and
http://www.fda.gov/cdrh/osb/guidance/1334.pdf.
Questions related to
QUALITY SYSTEM
GENERAL
Question. Should
my hospital comply with the Quality System regulation even if the SUDs that we
are reprocessing do not require premarket submissions to the FDA?
Answer. Yes. Regardless of whether or not the SUDs
that your hospital is reprocessing require
premarket submissions,
your hospital should comply with the requirements of the Quality System
regulation [which also is
referred to as the current Good Manufacturing Practice ( cGMP)] as described in
21 CFR Part 820 (see Appendix question #7 below). The following Internet web sites provide
information about the requirements of the regulation:
information about the requirements of the regulation:
http://www.FDA.gov/CDRH/dsma/gmpman.html -
Medical Device Quality Systems Manua l:
A Small Entity Compliance Guide
A Small Entity Compliance Guide
http://www.FDA.gov/CDRH/comp/designgd.html - Design Control
Guidance for Medical
Device Manufacturers
Device Manufacturers
http://www.FDA.gov/ora/inspect_ref/igs/qsit/qsitguide.pdf - Quality System
Inspection
Technique (QSIT) Handbook
Technique (QSIT) Handbook
Question. Is
the CEO of a hospital responsible for quality policy and implementation under
the Quality System (QS) regulation?
Answer. Under 21 CFR 820.20 (Management
responsibility) management with executive
responsibility is the
level of management that has the authority to establish and make changes to the
facility’s quality
policy. The implementation of the
quality system may be delegated;
however, it is up to the highest level of management to establish quality
policy and ensure implementation.
Management reinforces
understanding of policies and objectives by demonstrating a commitment to the
quality system visibly and actively on a continuous basis. This can be demonstrated by providing
adequate training and resources to support quality system development and
implementation.
Question. What
sterilization activities does FDA expect in a hospital reprocessor that is reprocessing single-use devices (SUDs)?
Answer. A
hospital reprocessor that reprocesses SUDs is considered a device manufacturer
as
defined under 21 CFR
820.3(o). As such, FDA expects that its
sterilization reprocessing of SUDs will
meet the requirements of the Quality System (QS) regulation (21 CFR Part 820). This regulation is
applicable to the sterilization activities in many ways. Several key elements affect whether a device is
sterile or nonsterile and whether it will function as intended at the conclusion of the process. The
success of a sterilization process is dependent to a large degree on how well the hospital reprocessor:
meet the requirements of the Quality System (QS) regulation (21 CFR Part 820). This regulation is
applicable to the sterilization activities in many ways. Several key elements affect whether a device is
sterile or nonsterile and whether it will function as intended at the conclusion of the process. The
success of a sterilization process is dependent to a large degree on how well the hospital reprocessor:
·has validated the sterilizing equipment and
process;
·controls the routine processing; and
·reaches decisions to assure that only a
sterile product is released for use.
A hospital SUD
reprocessor should prove during validation studies that each sterilization
process is
capable of achieving
sterility for each run (21 CFR 820.75).
The sterilization process should achieve a
sterility assurance level (SAL) of 10-6 for devices used in normally sterile areas of the body. A hospital
reprocessor cannot just assume that standard sterilizer cycles will effectively and safely reprocess
devices; it should demonstrate with microbiological lethality study data that the SAL is achieved by the
process utilized. Also, a hospital reprocessor should develop evidence that the sterilization process
does not have an adverse impact on the materials or functioning of the SUDs being reprocessed.
sterility assurance level (SAL) of 10-6 for devices used in normally sterile areas of the body. A hospital
reprocessor cannot just assume that standard sterilizer cycles will effectively and safely reprocess
devices; it should demonstrate with microbiological lethality study data that the SAL is achieved by the
process utilized. Also, a hospital reprocessor should develop evidence that the sterilization process
does not have an adverse impact on the materials or functioning of the SUDs being reprocessed.
Process controls used for
routine sterilization should be adequate to assure that the specifications for
process parameters established during validation are always met [21 CFR 820.70(2)]. By doing
validation studies, a hospital reprocessor can prove that when certain parameters (for example,
temperature or humidity) are used, sterility will be achieved. A hospital reprocessor should establish
controls over the routine processing to assure that the specifications for these parameters are met during
each run.
process parameters established during validation are always met [21 CFR 820.70(2)]. By doing
validation studies, a hospital reprocessor can prove that when certain parameters (for example,
temperature or humidity) are used, sterility will be achieved. A hospital reprocessor should establish
controls over the routine processing to assure that the specifications for these parameters are met during
each run.
Finally, a hospital
reprocessor should have procedures for releasing the SUDs for use, so that any
possibly non-sterile
reprocesssed SUD is detectable [21 CFR 820.80(d)]. It should review
documentation from each
run to be sure that the parameter specifications have been met. Many hospital
reprocessors also include biological confirmation of sterility by using biological indicators ( BIs) with
each run. While FDA strongly encourages the use of biological indicators, there may be circumstances
when the validation studies and the process controls are so rigorous that BIs might not be needed. In
these cases, the process should meet the parametric releases that are defined in recognized consensus
standards.
reprocessors also include biological confirmation of sterility by using biological indicators ( BIs) with
each run. While FDA strongly encourages the use of biological indicators, there may be circumstances
when the validation studies and the process controls are so rigorous that BIs might not be needed. In
these cases, the process should meet the parametric releases that are defined in recognized consensus
standards.
Question. What
kinds of documentation should a hospital reprocessor maintain for sterilization
reprocessing of SUDs?
Answer.
A
hospital that reprocesses SUDs should maintain written procedures and data to
show that it is
meeting requirements of relevant portions of the Quality System (QS) regulation
(21 CFR Part 820). In the area of sterilization, a hospital reprocessor should
maintain documentation to show that equipment has been installed correctly and
operates as intended. Likewise, it
should have documentation that
shows the sterilization process has been validated as being effective in achieving sterility without
adversely affecting the devices [21 CFR 820.75(a)]. Also, a hospital reprocessor should maintain
documentation for process control procedures and data to prove that for each run the specifications for sterilization parameters have been met [21CFR 820.70(a) and 820.184]. FDA may also ask to see any test results relating to the validation or routine sterilization of SUDs.
shows the sterilization process has been validated as being effective in achieving sterility without
adversely affecting the devices [21 CFR 820.75(a)]. Also, a hospital reprocessor should maintain
documentation for process control procedures and data to prove that for each run the specifications for sterilization parameters have been met [21CFR 820.70(a) and 820.184]. FDA may also ask to see any test results relating to the validation or routine sterilization of SUDs.
Question. What guidance is applicable to hospital reprocessors
that are sterilizing SUDs?
Answer. FDA has guidance documents that apply
generally to all types of manufacturing processes
including
sterilization. For example, the
“Guideline on General Principles of Process Validation” applies
to sterilization activities as well as to other manufacturing processes. This document is located on the
Internet at www.fda.gov/cdrh/ode/425.pdf. FDA documents relating to the Quality System (QS)
regulation also are applicable for sterilization processes. These documents are located on the Internet at
www.fda.gov/cdrh/dsma/cgmphome.html. General guidance is available from other sources such as the
Global Harmonization Task Force document entitled "Process Validation Guidance for Medical Device
Manufacturers."
to sterilization activities as well as to other manufacturing processes. This document is located on the
Internet at www.fda.gov/cdrh/ode/425.pdf. FDA documents relating to the Quality System (QS)
regulation also are applicable for sterilization processes. These documents are located on the Internet at
www.fda.gov/cdrh/dsma/cgmphome.html. General guidance is available from other sources such as the
Global Harmonization Task Force document entitled "Process Validation Guidance for Medical Device
Manufacturers."
Many national and
international consensus standards provide specific sterilization
processes. We
encourage you to become
familiar with these standards. FDA has
worked closely with other experts
from industry, healthcare facilities, and academia in developing these standards for the various types of
sterilization processes commonly used for medical devices. FDA recognizes many of these standards as
providing acceptable guidance for good sterilization practices. Although acceptable to FDA, these
standards are voluntary, and there is no regulatory requirement that they be followed. If these standards
are not followed, FDA expects that processing will meet the same levels of scientific soundness as the
standards. The FDA consensus standards program is described on the Internet at
www.fda.gov/cdrh/stdsprog.html. A list of standards useful in the reprocessing sterilization of SUDs is
located at www.fda.gov/cdrh/reuse/reuse-standards.shtml. Although consensus standards for the
sterilization of medical devices have been directed either to healthcare facilities or to industrial users,
many are being rewritten to include both types of facilities. For example, in the area of sterilization
methods commonly used in hospitals (moist heat or ethylene oxide), there are standards for both
industrial users and for healthcare facilities, as follows:
from industry, healthcare facilities, and academia in developing these standards for the various types of
sterilization processes commonly used for medical devices. FDA recognizes many of these standards as
providing acceptable guidance for good sterilization practices. Although acceptable to FDA, these
standards are voluntary, and there is no regulatory requirement that they be followed. If these standards
are not followed, FDA expects that processing will meet the same levels of scientific soundness as the
standards. The FDA consensus standards program is described on the Internet at
www.fda.gov/cdrh/stdsprog.html. A list of standards useful in the reprocessing sterilization of SUDs is
located at www.fda.gov/cdrh/reuse/reuse-standards.shtml. Although consensus standards for the
sterilization of medical devices have been directed either to healthcare facilities or to industrial users,
many are being rewritten to include both types of facilities. For example, in the area of sterilization
methods commonly used in hospitals (moist heat or ethylene oxide), there are standards for both
industrial users and for healthcare facilities, as follows:
STERILIZATION
METHOD
ETHYLENE OXIDE
|
INDUSTRIAL
FACILITY USE
ISO 11135
|
HEALTHCARE
FACILITY USE
ANSI/AAMI ST 41
|
MOIST HEAT
|
ISO 11134
|
ANSI/AAMI ST 46
|
Note that ANSI/AAMI ST 41 states that it does
not cover the reprocessing of items labeled for single-use only. Revisions of ANSI/AAMI ST 46 have been
written and indicate a similar exclusion for reprocessing of SUDs.
When deciding which
standards to use for sterilization of SUDs, remember that FDA considers
hospitals to be manufacturers if they
reprocess SUDs. FDA, therefore, expects
hospitals will meet either
the requirements of the industrial standards or have an equally rigorous
scientific rationale for sterilization
procedures used in reprocessing SUDs.
Question related to
Center for Medicare and Medicaid Services
(formerly the Health Care Financing Administration)
Question. Will
FDA work with the Center for Medicare and Medicaid Services (formerly the
Health Care
Financing Administration) to link compliance to reimbursement or participation
in Medicare and Medicaid programs?
Answer. Yes.
FDA and the Center for Medicare and Medicaid Services (CMS) have agreed
to work together
to ensure that hospitals reprocessing SUDs are doing so safely. FDA plans to inform CMS of any hospital SUD
reprocessor not in compliance with FDA's reprocessing requirements.
Questions related to
APPENDIX A
Question. If
a particular device is listed in Appendix A ( List of SUDs known to be
reprocessed)
of the August 14 guidance document, does that mean FDA believes the device can be safely
reprocessed?
of the August 14 guidance document, does that mean FDA believes the device can be safely
reprocessed?
Answer.
No. Appendix A is simply a list
of those types of devices that FDA believes
have been
reprocessed. It does not mean that a particular type of
device can or cannot be reprocessed safely.
In fact,
such a list would be impossible to develop.
Whether or not a device can be reprocessed safely depends not only on the
device but on the reprocessor and the methods used for cleaning and
sterilizing. Because of materials used or design of the device, some models
within a particular type of device may be able to be reprocessed safely while
others may not.
Question. If
a device is identified as "Exempt" on the List of SUDs (Appendix A),
is it exempt from both premarket and non-premarket requirements?
Answer. No. A
"Y" (yes) in the column identified as "Exempt (Y/N)?" means
that the device is exempt
from the premarket requirements only. It does not provide any information on whether or not the
device is exempt from any of the non- premarket regulatory requirements. A revised list that includes a
column titled "Premarket Exempt" and another column titled "GMP Exempt" has been provided to
clarify the types of exemptions that apply to a particular type of device. That list can be found on the
Internet at www.fda.gov/cdrh/reuse/1168a.html .
from the premarket requirements only. It does not provide any information on whether or not the
device is exempt from any of the non- premarket regulatory requirements. A revised list that includes a
column titled "Premarket Exempt" and another column titled "GMP Exempt" has been provided to
clarify the types of exemptions that apply to a particular type of device. That list can be found on the
Internet at www.fda.gov/cdrh/reuse/1168a.html .
Questions related to
SPECIFIC DEVICES
Question. Where
can I obtain specific guidance for the SUD that I am interested in reprocessing?
Answer. You
can search for guidance on a specific device on our Internet web site at
Question. How
can I obtain information on the status of a premarket notification [510(k)]
submission or a premarket approval (PMA) application for a reprocessed SUD?
Answer. The
status of an application under FDA review is confidential. Once an application has been
cleared or approved, it is included in FDA's releasable database on the Internet at
http://www.fda.gov/cdrh/databases.html. Click on the Premarket Notifications Database [510(k)s] or
the Premarket Approvals Database (PMA).
cleared or approved, it is included in FDA's releasable database on the Internet at
http://www.fda.gov/cdrh/databases.html. Click on the Premarket Notifications Database [510(k)s] or
the Premarket Approvals Database (PMA).
Question related to
REGISTRATION AND DEVICE LISTING
Question. Howdo we register our
facility and list the SUDs that we are reprocessing?
Answer. A medical device establishment that is
registering for the first time should complete form FDA
2891 (Initial Registration of Device Establishment). Enter the establishment type code "MB" for a
reprocessor if the form you receive does not have the code preprinted on it. You should list all SUDs
that your facility reprocesses. Submit a form FDA 2892 (Device Listing) for each type of device being
reprocessed. Information on how to obtain blank registration and listing forms and how to complete
them is located on the Internet at http://www.fda.gov/cdrh/reglistpage.html.
2891 (Initial Registration of Device Establishment). Enter the establishment type code "MB" for a
reprocessor if the form you receive does not have the code preprinted on it. You should list all SUDs
that your facility reprocesses. Submit a form FDA 2892 (Device Listing) for each type of device being
reprocessed. Information on how to obtain blank registration and listing forms and how to complete
them is located on the Internet at http://www.fda.gov/cdrh/reglistpage.html.